NasdaqGM:HROWPharmaceuticals
Should Vevye’s CVS Formulary Win Prompt a Closer Look from Harrow (HROW) Investors?
Harrow, Inc. recently presented at major industry events and secured a key win as its dry eye therapy Vevye replaced Xiidra on the CVS Tier 1 formulary.
This change gives Vevye first-line access at the largest pharmacy benefit manager in the US, which could significantly broaden adoption of Harrow’s flagship product.
We’ll explore how Vevye’s elevated CVS formulary status may influence Harrow’s growth profile and long-term investment outlook.
Rare earth metals are an input to most high-tech...